News & Updates

TYK2 inhibitor for psoriatic arthritis clears phase II trial
TYK2 inhibitor for psoriatic arthritis clears phase II trial
26 Mar 2022

In the treatment of patients with psoriatic arthritis, the use of the selective TYK2 inhibitor deucravacitinib appears to be effective and well tolerated, leading to greater improvements in American College of Rheumatology (ACR) domains, enthesitis endpoints, and multiple patient-reported, psoriasis-related outcomes relative to placebo, as shown in the results of a phase II trial.

TYK2 inhibitor for psoriatic arthritis clears phase II trial
26 Mar 2022
Death risk higher among older patients likely to delay, miss medical care due to pandemic
Death risk higher among older patients likely to delay, miss medical care due to pandemic
25 Mar 2022
Wearable device eases patients with GERD into left-side sleeping
Wearable device eases patients with GERD into left-side sleeping
25 Mar 2022 byJairia Dela Cruz

For patients with gastroesophageal reflux disease (GERD), sleeping on the left side is ideal and alleviates nocturnal reflux symptoms. A wearable device can train these patients to sleep in the ideal position, as shown in a study.

Wearable device eases patients with GERD into left-side sleeping
25 Mar 2022
Healthy lifestyle lowers T2D hazard in genetically at-risk individuals
Healthy lifestyle lowers T2D hazard in genetically at-risk individuals
25 Mar 2022

A genetic predisposition to low birth weight and childhood obesity contributes to an increased risk of adult type 2 diabetes (T2D), suggests a study. These risks can be modified by adherence to a healthy lifestyle in adulthood, particularly among those at high genetic risk of childhood obesity.

Healthy lifestyle lowers T2D hazard in genetically at-risk individuals
25 Mar 2022